2 months ago
1
Natco Pharma volition motorboat its Semaglutide injection (multi dose vials) successful the home marketplace connected Saturday.
It volition beryllium disposable tomorrow, time 1 of patent expiry, the Hyderabad-based generic drugmaker said connected Friday. Semaglutide is the progressive constituent successful cause large Novo Nordisk’s Ozempic and Wegovy. It is indicated for attraction of adults with benignant 2 diabetes arsenic an adjunct to fare and exercise.
Last month, Natco had received Central Drugs Standard Control Organisation (CDSCO) support to manufacture and marketplace generic Semaglutide successful India successful multi dose vials and pen instrumentality based connected the objective examination study.
Semaglutide injection volition beryllium launched successful multi dose vials of antithetic strengths nether marque names Semanat and Semanfull. The MRP of the vials volition beryllium ₹1,290 per period for 2 mg/1.5ml and 4mg/3ml; and ₹1,750 for 8mg/3ml.
The merchandise successful pen instrumentality is expected to beryllium launched successful April, successful the terms set of ₹4,000-4,500 per month. Natco said it is the archetypal institution to connection generic Semaglutide successful multi dose vials with customised syringes. It is besides offering the merchandise to 3rd parties for co-marketing.
Separately, Eris Lifesciences, which past period had announced a concern with Natco for commercialisation of Semaglutide successful the country, said it volition motorboat the merchandise nether Sundae brand. A GLP-1 receptor agonist, Semaglutide has emerged arsenic a transformative therapy for Type 2 diabetes and value management, driven by beardown outcomes successful glycemic power and value reduction, it said.
